# Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

> **NCT04445389** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genexine, Inc.** · enrollment: 60 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** GX-19
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT04445389
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-17
- **Primary completion:** 2020-12-17
- **Final completion:** 2020-12-17
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The sponsor decided to change the investigational product for a strategic reason.
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445389, "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04445389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*